Temozolomide-based combination for advanced neuroendocrine neoplasms: a systematic review of the literature.
In this systematic review, we explored the value of using temozolomide (TMZ)-based combinations for advanced neuroendocrine neoplasms (NENs). Database search were conducted using the terms 'NENs' and 'TMZ' and 'systemic therapy.' Outcomes of interest included progression-free survival and overall survival, toxicities and tumor response. In total, 16 trials including 348 patients were included. Median progression-free survival ranged from 6 to 31 months. The disease control rate ranged from 65 to 100%. Frequently reported grade 3/4 toxicities were leukopenia, lymphopenia and elevated transaminases. The published clinical data suggest that TMZ-based combination with some anticancer agents (especially capecitabine) could be an effective treatment option for advanced low-intermediate grade NENs.